diabetes type 2

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathstroke (fatal and non fatal)

alpha-glucosidase inhibitors

not classified
Study 541   -
Study 656, 1994   -
Campbell et al, 1998   -
Bachmann et al, 1998   -
Koyasu, 2010        -
Chiasson et al, 1994     placeboLow risk of bias -
Hasche et al, 1999   placeboLow risk of bias -
Josse et al, 2003     placeboLow risk of bias -
Halimi, 2000     errorplacebo (add on to met)Low risk of bias -
Rosenstock, 1998     errorplacebo (add on to met)Low risk of bias negative
Van Gaal, 2001     miglitolplacebo (add on to met)Low risk of bias negative

angiotensin renin system blockade

not classified
HOPE (diabetic subgroup), 2000       ACE inhibitorsplaceboLow risk of bias suggesting -24%-32%
ADVANCE, 2007    NCTperindopril and indapamideplaceboLow risk of bias -
NAGOYA HEART, 2011      NCTvalsartanamlodipineRisk of bias negative
STOP-2 (ACEI vs CCB) (diabetic subgroup), 2000       ACE inhibitorcalcium-channel blockerExploratory negative 14%16%
STOP-2 (ACEI, diabetic subgroup), 2000       ACE inhibitordiuretic or beta-blockerExploratory negative-12%-12%
captopril
UKPDS 38, 1998     captopril or atenololcontrolExploratory suggesting -17%-42%
UKPDS 39, 1998     captoprilatenololExploratory negative 14%38%
CAPP (diabetic subgroup), 1999       captoprildiuretic and/or beta-blockersExploratory suggesting -46%3%
irbesartan
IPDM (150mg), 2001     irbesartanplaceboLow risk of bias suggesting
IDNT (irbesartan vs pbo), 2001     irbesartanplaceboLow risk of bias suggesting-8%
IDNT (irbesartan vs amlodipine), 2001     irbesartanamlodipineLow risk of bias suggesting4%
lisinopril
ALLHAT (lisi vs chlor, diabetic subgroup), 2002       lisinoprilchlorthalidoneLow risk of bias negative-1%6%
losartan
RENAAL, 2001     losartanplaceboLow risk of bias suggesting2%
olmesartan
ROADMAP, 2010        NCTolmesartanplaceboLow risk of bias suggesting 72%
ORIENT    NCTolmesartanplaceboLow risk of bias negative-4%

angiotensin-receptor blockers

not classified
ADVANCE, 2007    NCTperindopril and indapamideplaceboLow risk of bias -
NAGOYA HEART, 2011      NCTvalsartanamlodipineRisk of bias negative
irbesartan
IPDM (150mg), 2001     irbesartanplaceboLow risk of bias suggesting
IDNT (irbesartan vs amlodipine), 2001     irbesartanamlodipineLow risk of bias suggesting4%
losartan
RENAAL, 2001     losartanplaceboLow risk of bias suggesting2%
olmesartan
ROADMAP, 2010        NCTolmesartanplaceboLow risk of bias suggesting 72%
ORIENT    NCTolmesartanplaceboLow risk of bias negative-4%

anti hypertensive agents

not classified
INVEST (subgroup), 2003       verapamilcontrolnegative
HOPE (diabetic subgroup), 2000       ACE inhibitorsplaceboLow risk of bias suggesting -24%-32%
SCAT (diabetic subgroup), 2000       enalaprilplaceboLow risk of bias -
SOLVD (subgroup), 1996       enalaprilplaceboLow risk of bias negative-10%
ACTION, 1998     nifedipineplaceboLow risk of bias negative
PROGRESS (diabetic subgroup), 2001         perindoprilplaceboLow risk of bias suggesting-31%
EUROPA (PERSUADE substudy), 2005     perindoprilplaceboExploratory negative-15%-15%
ADVANCE, 2007    NCTperindopril and indapamideplaceboLow risk of bias -
ADVANCE, 2007      NCTperindopril and indapamideplaceboLow risk of bias suggesting-13%-6%
PROFESS, 2008     telmisartanplaceboLow risk of bias -
ACCORD (blood pressure), 2010          NCTintensiveusualRisk of bias suggesting5%-42%
HOT <=80 (diabetic subgroup), 1998       intensiveusualExploratory suggesting-44%-30%
ABCD normotensives, 1993     intensiveusualExploratory suggesting-8%-68%
JMIC-B (diabetic subgroup), 2004     nifedipineACE inhibitorExploratory negative-65%-42%
NAGOYA HEART, 2011      NCTvalsartanamlodipineRisk of bias negative
ASCOT (subgroup), 2008     amlodipineatenololLow risk of bias suggesting-2%-24%
ACCOMPLISH (diabetic subgroup), 2010        NCTbenazepril + amlodipinebenazepril + hydrochlorothiazideLow risk of bias suggesting-16%-9%
STOP-2 (ACEI vs CCB) (diabetic subgroup), 2000       ACE inhibitorcalcium-channel blockerExploratory negative 14%16%
NORDIL (diabetic subgroup), 2000     diltiazemdiuretic and/or beta-blockerExploratory negative7%7%
STOP-2 (ACEI, diabetic subgroup), 2000       ACE inhibitordiuretic or beta-blockerExploratory negative-12%-12%
STOP-2 (CCB, diabetic subgroup), 2000       calcium-channel blockerdiuretic or beta-blockerExploratory negative-21%-20%
DETAIL, 2004     temisartanenalaprilLow risk of bias negative8%8%
GEMINI, 2004     carvedilolmetoprololExploratory negative-26%48%
amlodipine
IDNT (amlodipine vs PBO), 2001       amlodipineplaceboLow risk of bias negative-12%
ALLHAT (amlodipine vs chlor, diabetic subgroup), 2002       amlodipinechlorthalidoneLow risk of bias negative-4%-11%
FACET, 1997     amlodipinefosinoprilRisk of bias suggesting-19%147%
candesartan
SCOPE (diabetic subgroup), 2003       candesartancontrolLow risk of bias negative-9%
captopril
UKPDS 38, 1998     captopril or atenololcontrolExploratory suggesting -17%-42%
UKPDS 39, 1998     captoprilatenololExploratory negative 14%38%
CAPP (diabetic subgroup), 1999       captoprildiuretic and/or beta-blockersExploratory suggesting -46%3%
chlorthalidone
SHEP (diabetic subgroup), 1996   chlorthalidoneplaceboLow risk of bias suggesting -26%-26%
intensive blood pressure lowering strategies
ABCD target (H) , 2000   more intensive blood pressure lowering strategieless intensive blood pressure lowering strategie type 2 diabetes suggesting-55%-2%
ABCD target (N) , 2002     more intensive blood pressure lowering strategieless intensive blood pressure lowering strategie type 2 diabetes suggesting-8%-68%
irbesartan
IPDM (150mg), 2001     irbesartanplaceboLow risk of bias suggesting
IDNT (irbesartan vs pbo), 2001     irbesartanplaceboLow risk of bias suggesting-8%
IDNT (irbesartan vs amlodipine), 2001     irbesartanamlodipineLow risk of bias suggesting4%
lisinopril
ALLHAT (lisi vs chlor, diabetic subgroup), 2002       lisinoprilchlorthalidoneLow risk of bias negative-1%6%
losartan
RENAAL, 2001     losartanplaceboLow risk of bias suggesting2%
LIFE (diabetic subgroup), 2002       losartanatenololLow risk of bias suggesting-39%-18%
metoprolol
MERIT-HF, 2005     metoprololplaceboLow risk of bias negative-19%
nidrendipine
Syst-Eur (diabetic subgroup), 1999     nitrendipineplaceboLow risk of bias suggesting-41%-68%
nifedipine
INSIGHT (diabetic subgroup), 2000       nifedipinecoamilozideLow risk of bias negative-25%-10%
nisoldipine
ABCD (hypertension), 1998     nisoldipineenalaprilLow risk of bias suggesting-23%57%
olmesartan
ROADMAP, 2010        NCTolmesartanplaceboLow risk of bias suggesting 72%
ORIENT    NCTolmesartanplaceboLow risk of bias negative-4%
ramipril
DIABHYCAR, 2004     ramiprilplaceboLow risk of bias negative 4%3%
DREAM, 2008       ramiprilplacebonegative-2%-50%

antidiabetic drugs

not classified
Cefalu, 1998   -
Hermann, 1994   -
Charpentier, 2001   -
YSRE0001    NCTrepaglinide???Low risk of bias -
UGDP   insulincontrolsuggesting-52%
UKPDS 33   insulincontrolnegative 70%
Derosa , 2009       nateglinideglibenclamide (add on MET)Low risk of bias -
AGEE-3783    NCTrepaglinidegliclazide -
PRESERVE-beta     nateglinideglyburide (add on MET) -
AGEE-1524    NCTrepaglinide + insulininsulin -
AGEE-3020   repaglinide + insulininsulin -
GLORIA    NCTmitiglinide+vogliboseinsulin glargine -
Horton DOUBLON, 2000       nateglinide + metforminmetformin -
ReMet    NCTrepaglinideMetforminLow risk of bias -
AGEE-1411    NCTrepaglinide + metforminmetformin -
Reform      NCTrepaglinideMetformin (add on insulin)Low risk of bias -
CDJN608AUS13   nateglinideplacebo -
CDJN608AUS13   nateglinideplacebo -
CDJN608A ES03   nateglinideplacebo -
NAVIGATOR     nateglinideplacebo -
Schwarz , 2008     nateglinideplaceboLow risk of bias -
Schwarz (study 2), 2008     nateglinideplaceboLow risk of bias -
Dashora , 2007     nateglinideplacebo (add on insulin)Low risk of bias -
Juurinen , 2009     nateglinideplacebo (add on insulin+MET)Low risk of bias -
NCT01037842    NCTmitiglinideplacebo (add on MET)Low risk of bias -
EX-1510-CT-003    NCTmitiglinideplacebo (add on MET)Low risk of bias -
NCT00402909    NCTnateglinideplacebo (add on standard treatment)Low risk of bias -
AGEE-1411    NCTmetformin + repagliniderepaglinide -
Rosenstock , 2004     nategliniderepaglinide -
AGEE-3705    NCTrepaglinide + metforminrepaglinide -
AGEE-3018   repaglinide + metforminrepaglinide -
Raskin , 2009      NCTrepaglinide + metforminrosiglitazone + metformin -
AGEE-3017    NCTrepaglinide + metforminSU or MET -
albiglutide
Rosenstock (30 mg weekly), 2009      NCTalbiglutide weeklyplacebo (add on MET)Exploratory suggesting
alogliptin
Nauck, 2009      NCTalogliptinplacebo (add on MET)Low risk of bias negative
dapagliflozin
Bailey (MB102014), 2010          NCTdapagliflozinplacebo (add on MET)Low risk of bias -
exenatide
Buse, 2011      NCTexenatide 20µg/dplacebo (add on insulin)Low risk of bias negative -100%
Fineman, 2003     exenatide other dosesplacebo (add on MER+/-SU)Exploratory -
DeFronzo 10µg/d, 2005          NCTexenatide 10µg/dplacebo (add on MET)Low risk of bias negative
DeFronzo 20µg/d, 2005      NCTexenatide 20µg/dplacebo (add on MET)Low risk of bias suggesting
Kim, 2007      NCTexenatide weeklyplacebo (add on MET)Exploratory negative
Gao, 2009      NCTexenatide 20µg/dplacebo (add on MET+/-SU)Low risk of bias suggesting
Buse 10µg/d, 2004          NCTexenatide 10µg/dplacebo (add on SU)negative
Buse 20µg/d, 2004     exenatide 20µg/dplacebo (add on SU) -
Kadowaki (trial 8683), 2009     exenatide 10µg/dplacebo (add on SU+/-MET/TZD)Exploratory negative
Kendall 10µg/d, 2005      NCTexenatide 10µg/dplacebo (add on SU+MET)Low risk of bias negative
Kendall 20µg/d, 2005      NCTexenatide 20µg/dplacebo (add on SU+MET)Low risk of bias suggesting